Asset
Valbenazine
Neurocrine Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02274558 | phase3 | completed | 2014-10-01 | 2015-09-01 | Neurocrine Biosciences | A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia |
| NCT01267188 | phase2 | completed | 2011-01-01 | 2011-03-01 | Neurocrine Biosciences | Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia |
| NCT01733121 | phase2 | completed | 2012-12-01 | 2013-12-01 | Neurocrine Biosciences | NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia |
| NCT01393600 | phase2 | completed | 2011-08-01 | 2012-02-01 | Neurocrine Biosciences | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder |
| NCT01688037 | phase2 | completed | 2012-09-01 | 2013-09-01 | Neurocrine Biosciences | NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study) |
FDA applications (0)
This company has no applications containing this asset.